WO2007033208A3 - Utilisation d’indirubine et de ses dérivés dans les traitements d’une infection par le vih et d’insuffisance cardiaque - Google Patents
Utilisation d’indirubine et de ses dérivés dans les traitements d’une infection par le vih et d’insuffisance cardiaque Download PDFInfo
- Publication number
- WO2007033208A3 WO2007033208A3 PCT/US2006/035559 US2006035559W WO2007033208A3 WO 2007033208 A3 WO2007033208 A3 WO 2007033208A3 US 2006035559 W US2006035559 W US 2006035559W WO 2007033208 A3 WO2007033208 A3 WO 2007033208A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- indirubin
- derivatives
- polypeptide sequence
- heart failure
- treatments
- Prior art date
Links
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 title abstract 8
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 title abstract 4
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 title abstract 4
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 108070000030 Viral receptors Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000027902 cell growth involved in cardiac muscle cell development Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L’invention concerne l’utilisation d’indirubine et de ses dérivés dans la réduction de la réplication du virus de l’immunodéficience humaine. Un tel agent thérapeutique et ses dérivés sont également décrits dans une application visant à réduire les effets d’une insuffisance cardiaque par l’administration d’indirubine ou d’un dérivé fonctionnellement actif de celle-ci en vue de modifier l’hypertrophie cellulaire au niveau du muscle cardiaque. L’indirubine et ses dérivés fonctionnels peuvent également être utilisés dans des compositions thérapeutiques de combinaisons antivirales contenant des polypeptides chimériques thérapeutiquement efficaces contenant une séquence polypeptidique enrobée de virus et une séquence polypeptidique de récepteur viral, la séquence polypeptidique de l’enveloppe virale et la séquence polypeptidique de récepteur viral étant liées et présentant une affinité de liaison ligand/récepteur.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71609705P | 2005-09-12 | 2005-09-12 | |
| US60/716,097 | 2005-09-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007033208A2 WO2007033208A2 (fr) | 2007-03-22 |
| WO2007033208A3 true WO2007033208A3 (fr) | 2009-05-22 |
Family
ID=37865533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2006/035559 WO2007033208A2 (fr) | 2005-09-12 | 2006-09-12 | Utilisation d’indirubine et de ses dérivés dans les traitements d’une infection par le vih et d’insuffisance cardiaque |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007033208A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009220462A1 (en) * | 2008-02-29 | 2009-09-11 | Merck Sharp & Dohme Corp. | CCR5 antagonists as prophylactics for preventing HIV infection and methods of inhibiting transmission of same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596539B1 (en) * | 1997-10-31 | 2003-07-22 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
| US20040254094A1 (en) * | 2000-10-11 | 2004-12-16 | The Trustees Of University Of Pennsylvania And Board Of Regents | Suppression of cyclin kinase activity for prevention and treatment of infections |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US20050171038A1 (en) * | 2004-01-30 | 2005-08-04 | Agouron Pharmaceuticals, Inc. | Therapeutic combinations |
-
2006
- 2006-09-12 WO PCT/US2006/035559 patent/WO2007033208A2/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596539B1 (en) * | 1997-10-31 | 2003-07-22 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
| US20040254094A1 (en) * | 2000-10-11 | 2004-12-16 | The Trustees Of University Of Pennsylvania And Board Of Regents | Suppression of cyclin kinase activity for prevention and treatment of infections |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US20050171038A1 (en) * | 2004-01-30 | 2005-08-04 | Agouron Pharmaceuticals, Inc. | Therapeutic combinations |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007033208A2 (fr) | 2007-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007022371A3 (fr) | Composes se liant aux recepteurs de chimiokine | |
| EP1521749B8 (fr) | Derives de phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine | |
| HRP20130406T1 (hr) | Medikamenti s aktivnošä†u prema receptoru hm74a | |
| WO2005121145A3 (fr) | Composes antiviraux heterocycliques | |
| MXPA03010402A (es) | Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina. | |
| EP1834637A4 (fr) | Preparation prophylactique/therapeutique contre une maladie due aux radicaux libres | |
| UA92000C2 (en) | 1-benzylindole-2-carboxamide derivatives | |
| WO2008057420A3 (fr) | Dérivés de triterpène étendus | |
| WO2007064968A3 (fr) | Compositions pharmaceutiques stables de 5,10 methylenetetrahydrofolate | |
| WO2007046868A3 (fr) | Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques | |
| MX2007004882A (es) | Derivados de xantina con actividad de receptor de hm74a. | |
| WO2006138259A3 (fr) | Composes de liaison aux recepteurs des chimiokines | |
| WO2009093264A3 (fr) | Combinaisons pharmaceutiques | |
| JP2002528502A5 (fr) | ||
| WO2006125194A3 (fr) | Derives de piperazine et leurs utilisations en tant qu'agents therapeutiques | |
| WO2007064448A3 (fr) | Traitement du cancer a l'aide de fts et de 2-desoxyglucose | |
| ZA202204624B (en) | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same | |
| WO2006138350A3 (fr) | Composes de liaison au recepteur de la chimiokine | |
| WO2005059107A3 (fr) | Composes de liaison aux recepteurs de la chemokine | |
| CA2143610A1 (fr) | Utilisation de norastemizole pour le traitement de troubles allergiques | |
| NZ703919A (en) | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins | |
| JP2003514025A5 (fr) | ||
| WO2007033208A3 (fr) | Utilisation d’indirubine et de ses dérivés dans les traitements d’une infection par le vih et d’insuffisance cardiaque | |
| AU2003283500A1 (en) | 1,4-diazabicyclo(3.2.2)nonanecarboxamide derivatives, preparation and therapeutic use thereof related to malfunction of nicotinic receptors | |
| WO2022125378A8 (fr) | Polythérapie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06803464 Country of ref document: EP Kind code of ref document: A2 |